Logo Image
In Brief
Spotlight

Calliditas’ Phase IIb trial of PBC treatment meets primary endpoint

Setanaxib was also found to be well-tolerated in the trial.

Latest news

Ariceum starts radionuclide Phase I trial in glioblastoma

Ariceum stated it is the first company to sponsor a clinical trial using Auger therapy in recurrent glioblastoma treatment.

Highlands Oncology and Paradigm report 45% rise in Northwest Arkansas trials

The partnership is said to have improved the productivity and efficiency of the research team.

Eisai adopts Medidata’s AI-driven platform for clinical trials

Medidata's Clinical Data Studio will be used to streamline trials and improve patient experience.

Viridian completes subject enrolment for Phase III trial of TED treatment

The company is on schedule to present the topline readout from the THRIVE-2 trial by the end of the year.

Non-Hodgkin’s lymphoma trials increase in the 5 years since 2019

57.5% of studies focus on the efficacy and safety of potential treatments for NHL in larger patient cohorts.

Passage Bio targets FDA to greenlight ALS gene therapy trial

Passage Bio’s gene therapy targets progranulin, which is impactful in frontal temporal dementia, ALS, and Alzheimer’s disease.

Trials to watch: Four biologics concluding pivotal COPD trials

As the first biologic for COPD could soon be approved by the FDA, other candidates are coming to the end of pivotal studies.